These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21524570)

  • 1. Re-challenging patients with oxaliplatin allergy: the successful use of a standardised pre-medication protocol in a single institute.
    Siu SW; Chan WL; Liu KY; Choy TS; Leung TW; Au KH
    Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):558-9. PubMed ID: 21524570
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
    Thomas RR; Quinn MG; Schuler B; Grem JL
    Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.
    Broome CB; Schiff RI; Friedman HS
    Med Pediatr Oncol; 1996 Feb; 26(2):105-10. PubMed ID: 8531847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated anaphylactic responses induced by oral challenge with ranitidine.
    Walker AI; Werfel S; Kick G; Przybilla B
    Acta Derm Venereol; 2010 Mar; 90(2):189. PubMed ID: 20169307
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
    Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
    Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity reaction to ranitidine: description of a case and review of the literature.
    Foti C; Cassano N; Panebianco R; Calogiuri GF; Vena GA
    Immunopharmacol Immunotoxicol; 2009; 31(3):414-6. PubMed ID: 19694603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaphylaxis following intravenous ranitidine: a rare adverse reaction of a common drug.
    Chopra D; Arora P; Khan S; Dwivedi S
    Indian J Pharmacol; 2014; 46(2):234-6. PubMed ID: 24741203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
    Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
    Nozawa H; Muto Y; Yamada Y
    Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
    Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
    J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.
    Shen Y; Li C; Liu W; Mao W; Qian H; Wang H; Xu Q
    Oncol Res; 2018 Jun; 26(5):801-807. PubMed ID: 29295722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
    Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
    Gammon D; Bhargava P; McCormick MJ
    Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylaxis treatment: the details.
    Ellrodt A
    CMAJ; 2003 Nov; 169(11):1148; author reply 1148-9. PubMed ID: 14638647
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
    Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
    Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin.
    Rosique-Robles D; Vicent Verge JM; Borrás-Blasco J; Giner-Marco V; Casterá E; Galan-Brotons A; Abad J
    Int J Clin Pharmacol Ther; 2007 Nov; 45(11):606-10. PubMed ID: 18077926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure.
    Lee SY; Kang HR; Song WJ; Lee KH; Han SW; Cho SH
    Cancer Chemother Pharmacol; 2014 May; 73(5):1021-9. PubMed ID: 24696124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin in colorectal cancer: an overview.
    Armand JP; Boige V; Raymond E; Fizazi K; Faivre S; Ducreux M
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):96-104. PubMed ID: 11049040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.